Advertisement
Canada markets close in 3 hours

  • S&P/TSX

    22,418.25
    +118.42 (+0.53%)
     

  • S&P 500

    5,297.85
    +0.75 (+0.01%)
     

  • DOW

    39,932.70
    +63.32 (+0.16%)
     

  • CAD/USD

    0.7345
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    79.56
    +0.33 (+0.42%)
     

  • Bitcoin CAD

    91,209.62
    +2,550.92 (+2.88%)
     

  • CMC Crypto 200

    1,371.62
    -2.23 (-0.16%)
     

  • GOLD FUTURES

    2,412.90
    +27.40 (+1.15%)
     

  • RUSSELL 2000

    2,095.59
    -0.66 (-0.03%)
     

  • 10-Yr Bond

    4.4140
    +0.0370 (+0.85%)
     

  • NASDAQ

    16,693.07
    -5.25 (-0.03%)
     

  • VOLATILITY

    12.23
    -0.19 (-1.53%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • CAD/EUR

    0.6756
    0.0000 (0.00%)
     
MARKETS LIVE BLOG:

STOCKS TREAD WATER WITH DOW POISED FOR NEW 40K LEVEL BID

Reddit signs partnership with OpenAI that will see ChatGPT integrate content from its forums

Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings

Zacks Equity Research
·3 min read

For the quarter ended March 2024, Qiagen (QGEN) reported revenue of $458.8 million, down 5.5% over the same period last year. EPS came in at $0.46, compared to $0.53 in the year-ago quarter.

The reported revenue represents a surprise of +0.73% over the Zacks Consensus Estimate of $455.5 million. With the consensus EPS estimate being $0.44, the EPS surprise was +4.55%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $25 million versus $23.82 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.1% change.

  • Sales by Product Groups- Diagnostic solutions- QuantiFERON: $101 million versus $105.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.8% change.

  • Sales by Product Groups- Genomics / NGS: $55 million versus $50.95 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a 0% change.

  • Sales by Product Groups- Other: $11 million versus $11.67 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -35.3% change.

  • Sales by Product Groups- PCR / Nucleic acid amplification: $68 million versus $70.87 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -11.7% change.

  • Sales by Product Groups- Diagnostic solutions- NeuMoDx: $9 million versus $11.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -30.8% change.

  • Sales by Product Groups- Sample technologies: $155 million versus $146.53 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -10.4% change.

  • Sales by Product Groups- Diagnostic solutions: $170 million versus the three-analyst average estimate of $174.25 million. The reported number represents a year-over-year change of +4.3%.

  • Revenue- Life Sciences: $215 million versus $208.53 million estimated by two analysts on average.

  • Sales by Product Groups- Diagnostic solutions- Other: $35 million versus the two-analyst average estimate of $35.07 million.

  • Revenue- Molecular Diagnostics: $244 million compared to the $247.55 million average estimate based on two analysts. The reported number represents a change of -2.4% year over year.

View all Key Company Metrics for Qiagen here>>>

Shares of Qiagen have returned -3.1% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

QIAGEN N.V. (QGEN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research